BriaCell Therapeutics Corp. Warrant (BCTXZ) Stock Price
BCTXZStock
$0.12
Market Cap—
P/E—
PEG Ratio—
Div yield—
Beta—
BCTXZ Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-53.20%
Price vs S&P 500 (4W)19.17%
VGM Score49.70
Industry Peers — Pharmaceuticals(571)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
BCTXZBriaCell Therapeutics Corp. Warrant | — | — | C | $0.12 |
| LLYEli Lilly & Co. | D | B | B | $1233.66 |
| JNJJohnson & Johnson | D | C | B | $273.14 |
| ABBVABBVIE INC. | D | C | B | $265.79 |
| MRKMerck & Co., Inc. | D | C | A | $156.45 |
| NVSNovartis AG | C | C | C | $159.98 |
| AZNAstraZeneca PLC | C | B | C | $169.66 |
| NVONovo-Nordisk A/S | B | C | C | $48.66 |
| ABTAbbott Laboratories | C | C | B | $116.13 |
| PFEPfizer Inc. | C | D | C | $28.57 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $552.85 |
About BriaCell Therapeutics Corp. Warrant
BriaCell Therapeutics is a clinical-stage biotechnology company developing targeted cell-based immunotherapies for cancer. Its lead program, Bria-IMT, is in late-stage clinical trials for breast cancer, while Bria-OTS is a personalized off-the-shelf immunotherapy platform targeting breast and prostate cancers. The company is pursuing combination therapy approaches through clinical collaborations to enhance treatment efficacy.